Insider Transactions in Q2 2021 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.38%
|
$105,000
$21.37 P/Share
|
|
Jun 18
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.36%
|
$30,000
$6.3 P/Share
|
|
Jun 10
2021
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.24%
|
$42,000
$21.48 P/Share
|
|
Jun 03
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.38%
|
$100,000
$20.61 P/Share
|
|
Jun 03
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.36%
|
$30,000
$6.3 P/Share
|
|
Jun 01
2021
|
David Cragg Chief HR & Admin Officer |
SELL
Open market or private sale
|
Direct |
14,999
-4.44%
|
$314,979
$21.63 P/Share
|
|
Jun 01
2021
|
David Cragg Chief HR & Admin Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,999
+4.25%
|
$89,994
$6.3 P/Share
|
|
May 20
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.38%
|
$115,000
$23.71 P/Share
|
|
May 20
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.36%
|
$30,000
$6.3 P/Share
|
|
May 13
2021
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.23%
|
$48,000
$24.42 P/Share
|
|
May 12
2021
|
Muna Bhanji Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
May 12
2021
|
Robert Califf Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+47.81%
|
-
|
|
May 12
2021
|
Santo J Costa Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
May 12
2021
|
L Patrick Gage Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+15.37%
|
-
|
|
May 12
2021
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+28.72%
|
-
|
|
May 12
2021
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+45.79%
|
-
|
|
May 12
2021
|
Sandford D Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+45.79%
|
-
|
|
May 12
2021
|
B Lynne Parshall Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
May 12
2021
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+45.79%
|
-
|
|
May 12
2021
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+47.81%
|
-
|
|
May 07
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.38%
|
$115,000
$23.21 P/Share
|
|
May 07
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.36%
|
$30,000
$6.3 P/Share
|
|
Apr 30
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.38%
|
$125,000
$25.87 P/Share
|
|
Apr 30
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.36%
|
$30,000
$6.3 P/Share
|
|
Apr 27
2021
|
Sandford D Smith Director |
SELL
Open market or private sale
|
Direct |
9,739
-84.1%
|
$262,953
$27.75 P/Share
|
|
Apr 27
2021
|
Sandford D Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,739
+45.68%
|
$97,390
$10.62 P/Share
|
|
Apr 26
2021
|
Sandford D Smith Director |
SELL
Open market or private sale
|
Direct |
5,000
-84.46%
|
$135,000
$27.0 P/Share
|
|
Apr 26
2021
|
Sandford D Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.79%
|
$45,000
$9.45 P/Share
|
|
Apr 23
2021
|
Sandford D Smith Director |
SELL
Open market or private sale
|
Direct |
5,000
-84.46%
|
$130,000
$26.5 P/Share
|
|
Apr 23
2021
|
Sandford D Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.79%
|
$45,000
$9.45 P/Share
|
|
Apr 15
2021
|
Sandford D Smith Director |
SELL
Open market or private sale
|
Direct |
10,714
-85.3%
|
$267,850
$25.25 P/Share
|
|
Apr 15
2021
|
Sandford D Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,714
+46.03%
|
$96,426
$9.1 P/Share
|
|
Apr 12
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.38%
|
$115,000
$23.56 P/Share
|
|
Apr 12
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.36%
|
$30,000
$6.3 P/Share
|
|
Apr 09
2021
|
Sandford D Smith Director |
SELL
Open market or private sale
|
Direct |
27,582
-83.03%
|
$634,386
$23.95 P/Share
|
|
Apr 09
2021
|
Sandford D Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
27,582
+45.35%
|
$193,074
$7.88 P/Share
|
|
Apr 08
2021
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.22%
|
$46,000
$23.39 P/Share
|
|
Apr 01
2021
|
Robert Califf Director |
BUY
Grant, award, or other acquisition
|
Direct |
204
+30.77%
|
$4,896
$24.44 P/Share
|
|
Apr 01
2021
|
L Patrick Gage Director |
BUY
Grant, award, or other acquisition
|
Direct |
767
+3.29%
|
$18,408
$24.44 P/Share
|
|
Apr 01
2021
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
409
+30.78%
|
$9,816
$24.44 P/Share
|
|
Apr 01
2021
|
Sandford D Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
409
+30.78%
|
$9,816
$24.44 P/Share
|
|
Apr 01
2021
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
409
+30.78%
|
$9,816
$24.44 P/Share
|
|
Apr 01
2021
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
204
+30.77%
|
$4,896
$24.44 P/Share
|
|
Apr 01
2021
|
John T Henderson Director |
SELL
Open market or private sale
|
Direct |
3,333
-13.04%
|
$76,659
$23.54 P/Share
|
|
Apr 01
2021
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+11.53%
|
$26,664
$8.64 P/Share
|